Urogen Pharma (URGN) Receives a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma (URGN), with a price target of $47.00. The company’s shares closed last Friday at $24.65.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 11.7% and a 53.1% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma with a $47.50 average price target, a 91.8% upside from current levels. In a report issued on May 7, Stifel Nicolaus also reiterated a Buy rating on the stock with a $46.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.88 and a one-year low of $13.12. Currently, Urogen Pharma has an average volume of 275.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.
Read More on URGN: